SOUTH SAN FRANCISCO, Calif., July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 79,890 stock options to eleven non-executive employees vesting over four years with a one-year cliff.
Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$13.69 |
| Daily Change: | 0.06 0.44 |
| Daily Volume: | 45,701 |
| Market Cap: | US$240.940M |
September 05, 2024 September 03, 2024 August 06, 2024 June 24, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
